Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Diabetic Neuropathic Pain Market to Proliferate, Assesses DelveInsight | Key Companies Active in the Domain – AstraZeneca, Eli Lilly and Company, Eisai, Helixmith, Lexicon, NeurogesX, Centrexion, Pure Green Pharmaceuticals

Published

on

<!– Name:DistributionId Value:8830816 –> <!– Name:EnableQuoteCarouselOnPnr Value:True –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:1091dded-bf30-4615-a435-f645c2538b74 –>

New York, USA, May 04, 2023 (GLOBE NEWSWIRE) — Diabetic Neuropathic Pain Market to Proliferate, Assesses DelveInsight | Key Companies Active in the Domain – AstraZeneca, Eli Lilly and Company, Eisai, Helixmith, Lexicon, NeurogesX, Centrexion, Pure Green Pharmaceuticals

The increasing prevalence of diabetes patients, rise in screening for pain among diabetics, increase in the geriatric population, and launch of newly approved drugs is likely to fuel the growth of the diabetic neuropathic pain market size during the forecast period (2023–2032).

DelveInsight’s Diabetic Neuropathic Pain Market Insights report includes a comprehensive understanding of current treatment practices, diabetic neuropathic pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Diabetic Neuropathic Pain Market Report

  • As per DelveInsight analysis, the diabetic neuropathic pain market is expected to grow positively owing to several underline factors during the study period (2019–2032).
  • DelveInsight’s analysis shows that diabetic neuropathic pain cases show an increasing trend in the forecasted period in the 7MM. 
  • Leading diabetic neuropathic pain companies such as AstraZeneca, Centrexion Therapeutics, Aptinyx, Pure Green Pharmaceuticals Inc., Eli Lilly and Company, Regenacy Pharmaceuticals LLC, Helixmith Co., Ltd., Vertex Pharmaceuticals Incorporated, Eisai Inc., NeuroBo Pharmaceuticals Inc., Dong-A ST Co., Ltd., Daiichi Sankyo, Inc., NeurogesX, Lexicon Pharmaceuticals, and others are developing novel diabetic neuropathic pain drugs that can be available in the diabetic neuropathic pain market in the coming years.
  • Some of the key therapies for diabetic neuropathic pain treatment include MEDI 7352, CNTX6016, NYX2925, CBD/PEA, LY3857210, Ricolinostat, Engensis, VX-548, E2007, DA-9801, DS-5565, Capsaicin Dermal Patch, LY3526318, LX9211, and others.
  • Several diabetic neuropathic pain therapies are awaiting approval, while some therapies are in the advanced stages of development. 

Discover which therapies are expected to grab the major diabetic neuropathic pain market share @ Diabetic Neuropathic Pain Market Report

Diabetic Neuropathic Pain Overview

Diabetic neuropathic pain is a well-known diabetes consequence and the leading cause of all neuropathic pain. Diabetic neuropathic pain affects almost one-third of all diabetic patients. It is defined as the presence of signs and symptoms of nerve dysfunction in diabetic individuals after all other explanations have been ruled out. Prolonged high blood sugar levels can harm nerves throughout the body, but diabetic neuropathic pain most impact the legs and feet.

Diabetic neuropathic pain is characterized by tingling, burning, sharp, shooting, lancinating feelings, and electric shocks. It is usually classified as moderate to severe, and it is often worse at night, causing sleep disruption. The discomfort might be persistent and accompanied by cutaneous allodynia, which can significantly impact the patient’s quality of life, limiting their capacity to do everyday tasks and negatively impacting their mood. Pain may also be a cause of withdrawal from recreational and social activities, and it may be linked to depression.

Diabetic Neuropathic Pain Epidemiology Segmentation

The diabetic neuropathic pain epidemiology section provides insights into the historical and current diabetic neuropathic pain patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The diabetic neuropathic pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Diabetic Neuropathic Pain Prevalent Cases
  • Diabetic Neuropathic Pain Diagnosed and Treatable Cases
  • Diabetic Neuropathic Pain Gender-specific Cases  
  • Diabetic Neuropathic Pain Type-specific Cases  

Download the report to understand which factors are driving diabetic neuropathic pain epidemiology trends @ Diabetic Neuropathic Pain Epidemiological Insights

Diabetic Neuropathic Pain Treatment Market 

Current diabetic neuropathic pain treatment has two key goals: to target the underlying pathophysiological processes to avoid nerve fiber loss and reduce the unpleasant symptoms of PDN to normalize physical and psychological functioning. Tricyclic agents (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), or -aminobutyric acid (GABA) analogs (gabapentin or pregabalin) are commonly recommended as first-line medications, followed by opioids and topical therapies. Diabetic neuropathic pain is typically treated with TCAs, SNRIs, and GABA analogs. 

In September 2004, the SNRI duloxetine (Cymbalta, Eli Lilly) was licensed as the first medicine to treat the neuropathic pain associated with diabetic neuropathic pain. Duloxetine inhibits neuronal serotonin and norepinephrine reuptake. Although the specific mechanism of action of the drug’s central pain-inhibitory effect is unknown, it is thought to be connected to the potentiation of serotonergic and noradrenergic activity in the CNS. Blocking norepinephrine reuptake, in particular, has been shown to help with neuropathic pain.

Since the 1960s, traditional anticonvulsants have been utilized to treat neuropathy. However, in 2004, the FDA approved newer anticonvulsants, such as pregabalin, to treat DPN’s neuropathic pain. Because of its effectiveness in lowering pain and pain-related sleep disturbance, AAN guidelines recommend pregabalin as the first-line therapy for diabetic neuropathic pain treatment. Japan’s PMDA approved Mirogabalin for diabetic neuropathic pain treatment in 2019. Daiichi Sankyo is undertaking clinical research for Mirogabalin in the United States, with a planned launch within the study period. 

To know more about diabetic neuropathic pain treatment, visit @ Diabetic Neuropathic Pain Treatment Drugs 

Key Diabetic Neuropathic Pain Therapies and Companies

  • MEDI 7352: AstraZeneca
  • CNTX6016: Centrexion Therapeutics
  • NYX2925: Aptinyx
  • CBD/PEA: Pure Green Pharmaceuticals Inc.
  • LY3857210: Eli Lilly and Company
  • Ricolinostat: Regenacy Pharmaceuticals LLC
  • Engensis: Helixmith Co., Ltd.
  • VX-548: Vertex Pharmaceuticals Incorporated
  • E2007: Eisai Inc.
  • DA-9801: NeuroBo Pharmaceuticals Inc./Dong-A ST Co., Ltd.
  • DS-5565: Daiichi Sankyo, Inc.
  • Capsaicin Dermal Patch: NeurogesX
  • LY3526318: Eli Lilly and Company
  • LX9211: Lexicon Pharmaceuticals

Learn more about the FDA-approved drugs for diabetic neuropathic pain @ Drugs for Diabetic Neuropathic Pain Treatment 

Diabetic Neuropathic Pain Market Dynamics

The diabetic neuropathic pain market is expected to change in the coming years. One of the primary aspects recognized to influence the growth of the neuropathic pain market is the discovery of new medications for the treatment of neuropathic and chronic pains. Companies are focused on clinical studies to find therapies to treat diabetic neuropathic pain effectively. For example, Eli Lilly produced duloxetine (LY248686) for diabetic peripheral neuropathic pain (DPNP), while Daichi developed mirogabalin for DPNP. Another factor driving the expansion of the diabetic peripheral neuropathic pain market is the development of point-of-care diagnostics to identify and evaluate diabetic peripheral neuropathic pain. DPNCheck by NeuroMetrix, for example, is a rapid, accurate, and quantitative nerve conduction test used to examine nerves to detect, stage, and monitor neuropathy objectively. 

Moreover, the diabetic neuropathic pain pipeline is highly robust; many possible therapies are being studied for diabetic neuropathic pain treatment, and it is safe to assume that the therapeutic space will substantially impact the diabetic neuropathic pain market throughout the forecast period. Furthermore, the expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and a further improvement in the diagnosis rate will likely boost the growth of the diabetic neuropathic pain market in the 7MM.

However, certain factors may affect the growth of the diabetic neuropathic pain market. The diabetic neuropathic pain market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the diabetic neuropathic pain market growth.

Report Metrics Details
Study Period 2019–2032
Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Base Year 2019
Key Diabetic Neuropathic Pain Companies AstraZeneca, Centrexion Therapeutics, Aptinyx, Pure Green Pharmaceuticals Inc., Eli Lilly and Company, Regenacy Pharmaceuticals LLC, Helixmith Co., Ltd., Vertex Pharmaceuticals Incorporated, Eisai Inc., NeuroBo Pharmaceuticals Inc., Dong-A ST Co., Ltd., Daiichi Sankyo, Inc., NeurogesX, Lexicon Pharmaceuticals, and others
Key Diabetic Neuropathic Pain Therapies MEDI 7352, CNTX6016, NYX2925, CBD/PEA, LY3857210, Ricolinostat, Engensis, VX-548, E2007, DA-9801, DS-5565, Capsaicin Dermal Patch, LY3526318, LX9211, and others

Scope of the Diabetic Neuropathic Pain Market Report

  • Therapeutic Assessment: Diabetic Neuropathic Pain current marketed and emerging therapies
  • Diabetic Neuropathic Pain Market Dynamics: Attribute Analysis of Emerging Diabetic Neuropathic Pain Drugs
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Diabetic Neuropathic Pain Market Access and Reimbursement

Discover more about diabetic neuropathic pain drugs in development @ Diabetic Neuropathic Pain Clinical Trials

Table of Contents

1. Diabetic Neuropathic Pain Market Key Insights
2. Diabetic Neuropathic Pain Market Report Introduction
3. Diabetic Neuropathic Pain Market Overview at a Glance
4. Diabetic Neuropathic Pain Market Executive Summary
5. Disease Background and Overview
6. Diabetic Neuropathic Pain Treatment and Management
7. Diabetic Neuropathic Pain Epidemiology and Patient Population
8. Patient Journey
9. Diabetic Neuropathic Pain Marketed Drugs
10. Diabetic Neuropathic Pain Emerging Drugs
11. Seven Major Diabetic Neuropathic Pain Market Analysis
12. Diabetic Neuropathic Pain Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Related Reports

Diabetic Neuropathic Pain Pipeline

Diabetic Neuropathic Pain Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Diabetic Neuropathic Pain companies, including Clarity Pharmaceuticals Ltd, Eli Lilly and Company, Laboratorio Elea Phoenix S.A., PersonGen BioTherapeutics (Suzhou) Co., Ltd., among others.

Diabetic Neuropathy Market

Diabetic Neuropathy Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key diabetic neuropathy companies, including Goldfinch Bio, Novartis, Serodus, CURACLE, Daiichi Sankyo, among others.

Diabetic Neuropathy Pipeline

Diabetic Neuropathy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetic neuropathy companies, including Goldfinch Bio, Novartis, Serodus, CURACLE, Daiichi Sankyo, among others.

Diabetic Peripheral Neuropathy Pipeline

Diabetic Peripheral Neuropathy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetic peripheral neuropathy companies, including CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Helixmith, Aptinyx, Lexicon Pharmaceuticals, Lateral Pharma Pty Ltd., SIMR (Australia) Biotech Pty Ltd., WinSanTor, Inc., among others.

Diabetes Market

Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetes companies, including TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk, among others.

Type 1 Diabetes Market

Type 1 Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 1 diabetes companies, including Histogen, Novo Nordisk, Prevention Bio, among others.

Other Trending Reports

Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Diabetic Neuropathic Pain Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Overseas Expansion Strategy of K-OTT Introduced in France, KOCCA holds the ‘2024 Korea-France Content Forum’

Published

on

overseas-expansion-strategy-of-k-ott-introduced-in-france,-kocca-holds-the-‘2024-korea-france-content-forum’

– The ‘Korea-France Content Forum’ held to establish the Foundation for K-OTT’s oversea expansion
PARIS, May 24, 2024 /PRNewswire/ — The Ministry of Culture, Sports and Tourism (Minister Yu In-chon) and the Korea Creative Content Agency (President, Jo Hyun-rae, hereafter KOCCA) held the ‘2024 Korea-France Content Forum’ on May 24th during the Korea Expo in Paris, France.

The ‘2024 Korea-France Content Forum’ featured a keynote session (K-OTT’s Strategies in Global market) presenting K-OTT’s strategies for international expansion and a roundtable session (Strategies in the Era of Streaming) discussing the growth of OTT platforms and collaborative approaches with production companies.
The forum featured participation from various industry leaders including Kun hee Park (CEO, Wavve Americas), Sangjin Lee (Head of content IP Business, LG U+), Seung ae Sohn (Executive Director, Showbox), Ji ae Sohn (Ambassador for Cultural Cooperation), Moonju Kim (General Director, France Business Center, KOCCA), Isabelle Degeorges (President, Gaumont Television France) which produced the French Netflix original series, participated.
Strategy announcement by Wavve Americas (KOCAWA), the first K-OTT’s launched in Europe
During the Keynote Session, Park Kun Hee – CEO of Wavve Americas, the first domestic OTT Platform to launch services in Europe, Took the stage to discuss the international expansion strategy of KOCOWA, which started offering services in 39 countries including Europe since April of this year. Following this, Lee Sangjin, Head of Content IP Business of LG U+, presented the expansion strategy of LG U+ Mobile TV, encompassing diverse original content.
During the round-table session, participants shared thoughts and solutions regarding the survival strategies of local OTT platforms and production companies amidst the rapid waves of change brought about by the emergence of global OTT platforms.
In particular, through this forum, we were able to observe the proactive implementation of IP protection policies by local production companies in France, aimed at sustainable content creation. Isabelle Degeorges, CEO of Gaumont Television France, noted, “With the introduction of the European Audiovisual Media Services Directive (AVMSD), platforms and production companies can share IPs three years after supplying the content.” Kim Moon-joo, Director of the Korea Creative Content Agency’s France Business Center, participated as a panelist, introducing policies aimed at enhancing the competitiveness of K-OTT and fostering collaboration with production companies.
Park Kun Hee, CEO of Wavve Americas, who participated in the event, stated, “It was a meaningful opportunity to introduce our platform locally in Europe in line with KOCOWA’s expansion into the region”. Additionally, Kyoungbon Koo, Director Broadcasting & Video Content Division at KOCCA commented, “It was a meaningful occasion to not only introduce K-OTT’s strategies to Europe but also to exchange ideas on collaboration between Korea and France. We will continue to focus on activating various forms of collaboration with major international partners in the future”.
KOCCA supports the overseas expansion of excellent domestic OTT content and platforms through the newly established Local OTT Specialized Support Program this year. This initiative aims to enhance the competitiveness of domestic OTT platforms and content by adapting to the changing industrial environment.
Photo – https://mma.prnewswire.com/media/2421769/Korea_France_Content_Forum_Photo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/overseas-expansion-strategy-of-k-ott-introduced-in-france-kocca-holds-the-2024-korea-france-content-forum-302155362.html

Continue Reading

Artificial Intelligence

IoT Node and Gateway Market worth $604.7 billion by 2029 – Exclusive Report by MarketsandMarkets™

Published

on

iot-node-and-gateway-market-worth-$604.7-billion-by-2029-–-exclusive-report-by-marketsandmarkets™

CHICAGO, May 24, 2024 /PRNewswire/ — The IoT Node and Gateway market is projected to grow from USD 424.6 billion in 2024 and is estimated to reach USD 604.7 billion by 2029; it is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.3% from 2024 to 2029 according to a new report by MarketsandMarkets™. The growth of the IoT Node and Gateway market is driven by the Provision of increased IP address space through IPv6, Emergence of 5G technology, and Increasing need for data centers.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=248007097
Browse in-depth TOC on “IoT Node and Gateway Market”
410 – Tables70 – Figures390 – Pages
IoT Node and Gateway Market Report Scope:
Report Coverage
Details
Market Revenue in 2024
$ 424.6 billion
Estimated Value by 2029
$ 604.7 billion
Growth Rate
Poised to grow at a CAGR of 7.3%
Market Size Available for
2020–2029
Forecast Period
2024–2029
Forecast Units
Value (USD Million/Billion)
Report Coverage
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered
By Hardware, End-use Application and Region
Geographies Covered
North America, Europe, Asia Pacific, and Rest of World
Key Market Challenge
Requirement for wireless spectrum and licensed spectrum
Key Market Opportunities
Accelerated IoT adoption in healthcare sector
Key Market Drivers
Rising use of wireless smart sensors and networks
By Hardware, the Logic Devices are projected to grow at a high CAGR of IoT Node and Gateway market during the forecast period.
Logic devices can adapt to changing requirements even after deployment. As new features or functionalities are needed, the logic within the device can be reprogrammed to accommodate these changes, extending the useful life of the product and reducing the need for hardware revisions. The integration of FPGA technology into IoT devices further enhances these advantages. The integration of FPGAs into IoT nodes and gateways empowers manufacturers to develop highly optimized, customizable, and scalable solutions that meet the diverse needs of IoT applications. Tesla’s Full Self-Driving (FSD) computer utilizes FPGAs to handle complex neural network computations for autonomous driving algorithms. This allows them to potentially improve their FSD capabilities through software updates that reconfigure the logic within the FPGAs.
BFSI segment in IoT Node and Gateway Market is projected to grow at a highest CAGR during the forecast period.
BFSI sector can use IoT technology to provide more convenient solutions for customers. IoT can be used to perform data collection in real time and for instant communication between devices. For instance, it can facilitate cashless payments using an RFID scanner to identify products in the shopping cart and mobile wallet. The adoption of mobile point of sale (mPOS) systems and kiosks is fundamentally reshaping the landscape of the BFSI market. mPOS facilitates transactions anytime, anywhere, benefiting unbanked populations and enabling temporary service points for events. Kiosks offer convenient banking functionalities, reducing wait times and freeing up staff for complex inquiries. These technologies drive cost savings by requiring less investment and automating routine tasks, allowing resources to be reallocated strategically. They provide rich data for personalized services, fraud detection, and operational optimization. mPOS systems and kiosks promote financial inclusion by extending services to remote areas, fostering economic activity and well-being.
Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=248007097
North America accounts for the largest share in IoT Node and Gateway Industry.
The North American IoT market is poised to grow, driven by government efforts to transition cities into smart urban centers. The growing need for sophisticated IoT solutions, fueled by the widespread availability of high-speed data, will further propel market expansion in this region. Furthermore, North America’s dynamic IoT node and gateway ecosystem features established players like Intel Corporation (US), Texas Instruments Incorporated (US), Dell (US), and Cisco Systems (US), driving competition, innovation, and affordability. Increasing research and development at industry levels is broadening the application areas of IoT in various industries, such as retail, consumer electronics, automotive and transportation, and healthcare, especially in the US. The increased demand for effective solutions and focus on early, accurate, and fast diagnosis of diseases has led to huge investments in technological developments in the healthcare sector.
Key Players
Key companies operating in the IoT Node and Gateway companies are Intel Corporation (US), Qualcomm Technologies, Inc. (US), Texas Instruments Incorporated (US), STMicroelectronics (Switzerland), Microchip Technology Inc. (US), Huawei Technologies Co., Ltd. (China), NXP Semiconductors N.V. (Netherlands), Cisco Systems, Inc. (US), Hewlett Packard Enterprise Development LP (US), TE Connectivity Ltd (Switzerland), Advantech Co., Ltd. (Taiwan), Dell Technologies (US), among others.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=248007097
Browse Adjacent Market: Semiconductor and Electronics Market Research Reports &Consulting
Related Reports: 
IoT Technology Market by Node Component (Sensor, Memory Device, Connectivity IC, Processor, Logic Devices), Software Solution (Remote Monitoring, Data Management), Platform, Service, End-use Application, Geography – Global Forecast to 2029
Industrial IoT Market Size, Share & Industry Growth Analysis Report by Device & Technology, Connectivity Type, Software, Vertical (Manufacturing, Energy, Oil & Gas, Healthcare, Retail, Transportation, Metals & Mining, Agriculture), and Geography – Global Growth Driver and Industry Forecast to 2026
Internet of Robotic Things Market (IoRT) by Component (Sensor, Power, Control), Service (Professional, Managed), Platform (Device, Application, Network), Software (Analytics, Data, Security, Monitoring, Bandwidth), Application – Global Forecast to 2022
MulteFire Market by Device (Small Cells, Switches, Controllers), Application (Industrial Manufacturing, Commercial, Transportation, Public Venues, Healthcare, Oil & Gas and Mining, Power Generation, Hospitality), and Geography – Global forecast 2025
Smart Robots Market Size, Share by Component (Sensors, Actuators, Control Systems), Type, Operating Environment, Mobility, Application (Domestic, Field/Agricultural, Public Relations, Industrial), and Region – Global Forecast to 2025
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact: Mr. Aashish MehraMarketsandMarkets™ INC. 630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: [email protected] Our Web Site: https://www.marketsandmarkets.com/Research Insight: https://www.marketsandmarkets.com/ResearchInsight/iot-gateway-market.aspContent Source: https://www.marketsandmarkets.com/PressReleases/iot-gateway.asp
Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/iot-node-and-gateway-market-worth-604-7-billion-by-2029—exclusive-report-by-marketsandmarkets-302155034.html

Continue Reading

Artificial Intelligence

atNorth Wins ‘Colocation Provider of the Year’ and ‘Digital Infrastructure Project of the Year’ at Industry Award Events

Published

on

atnorth-wins-‘colocation-provider-of-the-year’-and-‘digital-infrastructure-project-of-the-year’-at-industry-award-events

AtNorth recognized at the Electrical Review & Data Centre Review Awards and the Tech Capital Awards.
REYKJAVÍK, Iceland, May 24, 2024 /PRNewswire/ — atNorth, the leading Nordic colocation, high-performance computing, and artificial intelligence service provider has today announced further acknowledgement in the industry as it wins two significant awards.

The business has been awarded the `Colocation Provider of the Year’ award at the Electrical Review & Data Centre Review Awards. atNorth has undertaken a significant expansion strategy in recent years, that has ensured that the business can offer high performance infrastructure at speed and scale. This award reflects the business’ growth journey as it continues to innovate and adapt to technological advancements and client requirements.
atNorth has also won the `Digital Infrastructure Project of the Year’ at the Tech Capital Awards for its work with client, Shearwater Geoservices.  The global marine imaging and processing leader achieved a 92% reduction in CO2 output and an 85% reduction in cost by moving a portion of its UK HPC infrastructure to one of atNorth’s Icelandic data center sites.
Fueled by the abundant renewable power sources of the Nordics, atNorth`s services deliver performance and efficiency for high density workloads in a sustainable way that enables clients to decarbonize their IT footprint and reduce overall costs.
Winners are voted for by a panel of industry experts for both awarding bodies in a process that aims to recognize the outstanding achievements within the digital infrastructure industry.
“We are thrilled to receive these acknowledgments for our data center services”, says Eyjólfur Magnús Kristinsson, CEO at atNorth. “atNorth has experienced significant growth over the last couple of years and this industry recognition is a testament to our dedication to delivering excellence across the board. We are determined to continue decarbonizing the world’s most demanding workloads in an efficient, sustainable, and cost-effective way.”
The news follows atNorth’s announcements of colocation clients Crusoe, BNP Paribas and Advania. The business has also received recent recognition from multiple other awarding bodies including; the Datacloud Global Awards, the Energy Awards, TechRound’s Sustainability60 and the UK Green Business Awards.  
About atNorth
atNorth is a leading Nordic data center services company that offers sustainable, cost-effective, scalable colocation and high-performance computing services trusted by industry-leading organizations. The business acquired leading High-Performance Computing (HPC) provider, Gompute, in 2023 enabling a compelling full stack offering tailored to AI and other critical high-performance workloads. 
With sustainability at its core, atNorth’s data centers run on renewable energy resources and support circular economy principles. All atNorth sites leverage innovative design, power efficiency, and intelligent operations to provide long-term infrastructure and flexible colocation deployments. The tailor-made solutions enable businesses to calculate, simulate, train and visualize data workloads in an efficient, cost-optimized way.
atNorth is headquartered in Reykjavik, Iceland and operates seven data centers in strategic locations across the Nordics, with additional sites to open in Helsinki, Finland and in Denmark in Q4 2024, as well as its tenth site ready for operation in Kouvola, Finland in 2025.
For more information, visit atNorth.com or follow atNorth on LinkedIn or Facebook.
Press Contact:Caroline BruntonKite Hill PR for atNorth+44 (0) 7796 274 [email protected]
This information was brought to you by Cision http://news.cision.com.
https://news.cision.com/atnorth/r/atnorth-wins–colocation-provider-of-the-year–and–digital-infrastructure-project-of-the-year–at-i,c3987735
The following files are available for download:
https://mb.cision.com/Main/18907/3987735/2820097.pdf
Release
https://news.cision.com/atnorth/i/awards,c3303761
Awards
https://news.cision.com/atnorth/i/ice03-02227-front-left-close,c3303762
ICE03 02227 front left close
 

View original content:https://www.prnewswire.co.uk/news-releases/atnorth-wins-colocation-provider-of-the-year-and-digital-infrastructure-project-of-the-year-at-industry-award-events-302155172.html

Continue Reading
Advertisement
Advertisement

Latest News

Trending